Compare PALI & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PALI | TCPC |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.7M | 308.8M |
| IPO Year | 2019 | 2006 |
| Metric | PALI | TCPC |
|---|---|---|
| Price | $2.03 | $3.32 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 7 | 2 |
| Target Price | ★ $11.29 | $3.50 |
| AVG Volume (30 Days) | ★ 4.7M | 874.8K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 18.23% |
| EPS Growth | ★ 97.06 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $260,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1500.39 | N/A |
| 52 Week Low | $0.55 | $3.08 |
| 52 Week High | $2.86 | $7.88 |
| Indicator | PALI | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 45.20 |
| Support Level | $1.57 | $3.08 |
| Resistance Level | $2.16 | $3.54 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 47.06 | 48.91 |
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.